Clinical Trial Update: A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response [Phase 2]

View source ↗

Summary

Phase II trial evaluating SGI-110 in patients with various high-risk myelodysplastic syndromes and related conditions not responding to prior hypomethylating th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• SGI-110 (guadecitabine)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: MDS | Phase 2 | Status: COMPLETED